Lebrikizumab in the personalized management of asthma

There is a need for improved therapies for severe asthma. Lebrikizumab, a humanized monoclonal antibody that binds to interleukin (IL)-13, is under development for the treatment of poorly controlled asthma. This article reviews the potential role of IL-13 in the pathogenesis of asthma, the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomson, Neil C, Patel, Manish, Smith, Andrew D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459551/
https://www.ncbi.nlm.nih.gov/pubmed/23055690
http://dx.doi.org/10.2147/BTT.S28666

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459551/
https://www.ncbi.nlm.nih.gov/pubmed/23055690
http://dx.doi.org/10.2147/BTT.S28666

Ejemplares similares